Treating severe sepsis with drotrecogin alfa (activated).
Severe sepsis is a complex condition with mortality rates ranging from 30 to 50% in spite of advances in critical care. Xigris (drotrecogin alfa (activated)) is associated with an absolute reduction in the risk of death of 6.1% and was granted European Union marketing authorization in August 2002.